Biomarker Technologies LLC' New Blood Test for Breast Cancer Seeks Future Test Candidates; Women And Physicians Needed For First-Of-Kind Test
10/19/2005 5:10:34 PM
PHOENIX--(BUSINESS WIRE)--May 3, 2005--Biomarker Technologies LLC, the worldwide technology provider of the BT Test(TM), is beginning a nationwide mobilization of women and physicians who want to become involved in upcoming clinical studies for this first-of-its-kind diagnostic blood test for breast cancer.
The company is seeking both healthy women and those with recently diagnosed breast cancer, as well as physicians who are interested in being contacted for more information. When new studies are launched, those who sign up will be contacted first with complete study details and requirements. The studies are part of the FDA Pre-Market Approval (PMA) process for the BT Test. The company is looking to submit data to the FDA in the near future.
comments powered by